Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma in Patients of Different Ages : Episode 5
Current and Emerging Treatment Options for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
A healthcare expert examines Mirdametinib as an investigational treatment for NF1-PN, focusing on its potential role in managing the condition in adolescents and adults who have moved beyond pediatric care.
EP: 1.UPCOMING SERIES: Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma in Patients of Different Ages
EP: 2.Treatment Options and Management of Neurofibromatosis Type 1 Related Plexiform Neurofibroma
EP: 3.Challenges When Managing Neurofibromatosis Type 1 Related Plexiform Neurofibroma
EP: 4.Transition of Care for Neurofibromatosis Type 1 Related Plexiform Neurofibroma from Adolescent to Adulthood
Now Viewing
EP: 5.Current and Emerging Treatment Options for Neurofibromatosis Type 1 Related Plexiform Neurofibroma
EP: 6.Importance of Multidisciplinary Care in Management of Neurofibromatosis Type 1 Related Plexiform Neurofibroma
- Mirdametinib is currently being investigated as a treatment option for adolescents and adults who have transitioned out of adolescent care who are living with NF1-PN. Can you comment on the recent phase II data?
Recent Videos
Related Content
